- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04333901
Compliance of Long-term Home Non-invasive Ventilation for Patients With Chronic Obstructive Pulmonary Disease
Assessment of the Home Non-invasive Compliance in Patients With Chronic Obstructive Pulmonary Disease Following the Introduction of Long-term Ventilation. An Observational Study
Background : Long-term home non-invasive ventilation (NIV) can be proposed as treatment for acute respiratory failure with severe alveolar hypoventilation. The aim of NIV is to correct both daytime and night-time hypoventilation and associated symptoms and to provide the patient with adequate night-time oxygen saturation. The benefits of long-term NIV in the management of chronic obstructive pulmonary disease (COPD) patients in a stable state remain controversial. This highlights the importance of identifying the predictive factors for good compliance to the NIV, defined as a use of more than 4 hours per day.
Aim of the study: The main objective is this observational study is to monitor the home NIV compliance over a period of 1 year under real conditions of treatment in patients with COPD newly initiated onto NIV (with telemonitoring or not) in order to specify the predictive criteria for good compliance. The secondary objectives are to assess the evolution of functional respiratory data, NIV parameters and changes in prescription, occurrence of acute exacerbations of COPD, hospitalizations and death, patient outcomes (quality of life and acceptability of NIV).
Study design: a cohort of 120 patients with COPD newly initiated onto home-NIV (with telemonitoring or not), either in a stable state or following an acute exacerbation will be enrolled in the study and follow-up over 1 year. Data will be collected by lung specialists and home health care provider teams at 1-month post-initiation of NIV, 6 months and 1 year. The study is conduct in France.
Study Overview
Status
Conditions
Study Type
Enrollment (Actual)
Contacts and Locations
Study Locations
-
-
-
Aix-en-Provence, France, 13616
- Pays d'Aix hospital
-
Cannes, France, 06414
- cannes Hospital
-
Créteil, France, 94010
- Henri-Mondor Hospital (APHP)
-
Lamotte-Beuvron, France, 41600
- Institut Médical de Sologne Les Pins
-
Montivilliers, France, 76290
- Le Havre Jacques Monod hospital
-
Paris, France, 75877
- Bichat Hospital
-
Paris, France, 75013
- Pitié Salpétrière hospital (APHP)
-
Saint-Nazaire, France, 44600
- Saint-Nazaire Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- COPD patients who require the initiation of a home-NIV (in case of previous equipment: NIV interrupted for more than 6 months).
- Life expectancy greater than 1 year.
- Patient who has agreed to participate in the observational study after receiving clear information from the investigator and signing the consent form.
Exclusion Criteria:
- NIV indicated for the treatment of chronic respiratory failure other than COPD.
- Patient with overlap syndrome (COPD associated to OSA).
- Patient with limitations who do not allow proper use of the NIV device.
- Simultaneous participation in a health intervention research.
Study Plan
How is the study designed?
Design Details
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Assessment of the global compliance of the home-NIV over 1 year
Time Frame: 1 year
|
For each patient, the total number of hours of NIV use divided by the number of days over the period of observation will be calculated.
|
1 year
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Evolution of the mean duration of NIV use per day
Time Frame: month 1, month 6, month 12
|
The mean number of hours of NIV use per day will be calculated by period of 30 consecutive days at different times over the year of home NIV introduction. At each time, the proportion of patients with NIV use ≥ 4 hours per day will be calculated. |
month 1, month 6, month 12
|
Impact of the home-NIV on the medical condition of COPD patients
Time Frame: 1 year
|
The number of hospitalizations, COPD exacerbations, deaths will be monitored over 1 year.
|
1 year
|
Impact of the home-NIV on the dyspnea
Time Frame: At inclusion, month 6, month 12
|
The respiratory function will be evaluated with the score of dyspnea assessed using the Modified Medical Research Council (mMRC) scale. The score ranges from 0 to 4 points; higher scores mean a high dyspnea. |
At inclusion, month 6, month 12
|
Impact of the home-NIV on the respiratory function
Time Frame: At inclusion, month 6, month 12
|
The pulmonologist will assess the evolution of respiratory function according to good medical practice with the pulmonary functional tests and blood gas analysis, and judge if the prescribed home-NIV treatment is sufficient to normalize the respiratory function or if the treatment must be modified.
|
At inclusion, month 6, month 12
|
Impact of the home-NIV on the health related quality of life of COPD patients
Time Frame: At inclusion, month 6
|
the quality of life will be assessed using the COPD-specific health related quality of life questionnaire named VQ11.
The questionnaire VQ11 comprises 11 items distributed across three components (functional: 3 items, psychological: 4 items, social: 4 items).
The global score ranges from 11 to 55 points; higher scores mean a better quality of life.
|
At inclusion, month 6
|
Assessment of home-NIV by patients
Time Frame: month 6
|
The home-NIV treatment will be assessed by patients using the S3-NIV questionnaire (this short questionnaire comprises 11 items distributed across three NIV-related components : respiratory Symptoms, Sleep quality and NIV-related Side effects.
The global score varies between 0 to 10 points; higher scores mean a better outcome.
|
month 6
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Gilles Jébrak, MD, Bichat Hospital, Paris
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- VENTIOBS
- IDRCB 2019 A01902-55 (Other Identifier: French National Health Agency)
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Chronic Obstructive Pulmonary Disease
-
Spire, Inc.ResMedCompletedSevere Chronic Obstructive Pulmonary Disease | Moderate Chronic Obstructive Pulmonary DiseaseUnited States
-
Karaganda Medical UniversityCompletedChronic Obstructive Pulmonary Disease | Chronic Obstructive Pulmonary Disease Moderate | Chronic Obstructive Pulmonary Disease SevereKazakhstan
-
Randall DebattistaUniversity of Malta, Faculty of Health SciencesNot yet recruitingChronic Obstructive Pulmonary Disease Moderate | Acute Exacerbation of COPD | Chronic Obstructive Pulmonary Disease Severe
-
Cukurova UniversityCompletedAnesthesia | Chronic Obstructive Pulmonary Disease Moderate | Lungcancer | Chronic Obstructive Pulmonary Disease Severe | Chronic Obstructive Pulmonary Disease MildTurkey
-
National Taipei University of Nursing and Health...TerminatedChronic Pulmonary Disease | Chronic Obstructive Pulmonary Disease Exacerbation | Chronic Obstructive Pulmonary Disease With ExacerbationTaiwan
-
Taipei Medical UniversityUnknownChronic Obstructive Pulmonary Disease Severe | Chronic Obstructive Pulmonary Disease End StageTaiwan
-
Kırıkkale UniversityRecruitingCOPD (Chronic Obstructive Pulmonary Disease)Turkey
-
Hopital FochAir Liquide SARecruitingChronic Obstructive Pulmonary Disease SevereFrance
-
Fundación para la Investigación del Hospital Clínico...Not yet recruitingCOPD, Chronic Obstructive Pulmonary DiseaseSpain
-
Canandaigua VA Medical CenterRecruitingChronic Obstructive Pulmonary Disease ModerateUnited States